Genzyme is again shipping Thyrogen following an equipment-related delay last week. Faulty fill/finish equipment had stifled production of the cancer treatment at the company's beleaguered Boston-area plant.
Meanwhile, supplies of its top-selling drugs, Cerezyme and Fabrazyme, continue to rise toward pre-plant-shutdown levels.
Under its FDA consent decree, Genzyme had to restrict Thyrogen production to only what was medically necessary, reports Dow Jones, so surplus supplies are unavailable. The company plans to move the fill/finish operation out of the Allston site in accordance with the consent decree.
Cerezyme supplies also are on the rise. Remediation work is proceeding "as expected," the company says. U.S. patients have already returned to their normal dosing schedules and the company expects worldwide supply to return to normal by the end of the year.